{
  "compound": "Cannabis and cannabinoids",
  "condition": "IBD_CROHNS",
  "effect_size": "N/A (guideline)",
  "study_type": "CLINICAL_GUIDELINE",
  "source": "NORML:IBD_GUIDELINE_001",
  "participants": "Expert consensus and evidence review",
  "year": 2020,
  "notes": "European Crohn's and Colitis Organisation Position Statement on Cannabis",
  "confidence": "medium",
  "abstract": "Evidence level: Moderate for symptom improvement; Insufficient for remission induction; Safe as adjunct therapy; Need for standardized formulations"
}